Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Genetic Technologies ( (GENE) ) has shared an update.
Genetic Technologies Limited has received a delisting notice from Nasdaq following the appointment of voluntary administrators due to financial issues, indicating that its securities will be removed from trading on December 17, 2024. The delisting follows concerns about the company’s residual equity interest and compliance with Nasdaq’s listing requirements, particularly due to a deficiency in shareholders’ equity. Although the company can appeal, the administrators do not plan to do so, and the delisting does not affect its listing on the Australian Securities Exchange.
More about Genetic Technologies
Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) is a diversified molecular diagnostics company and a global leader in genomics-based tests for health, wellness, and serious diseases through its geneType™ and EasyDNA brands. The company offers cancer predictive testing and assessment tools to enhance health outcomes worldwide, utilizing a proprietary risk stratification platform developed over a decade. They lead in risk prediction for oncology, cardiovascular, and metabolic diseases, continually developing risk assessment products.
YTD Price Performance: -67.86%
Average Trading Volume: 22,377
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $6.06M
For detailed information about GENE stock, go to TipRanks’ Stock Analysis page.
